Page 100 - Clinical Development News Today

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of

Incannex has engaged Fortrea to manage the phase 2/3 clinical trial investigating IHL-42X for the treatment of obstructive sleep apnea.

Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed two-decade veteran Dr Ron Weitzman as its interim chief medical officer, replacing Dr Giovanni Selvaggi. Dr...

– Key Initiatives Highlight the Role of Catalytic Collaboration to Help Advance Health Equity – – Latest HIV Research and Development Data Drive the Next Wave of Person-Centric Scientific Discovery in Treatment, Prevention and Novel Research Strategies in HIV Cure –

Liz Beatty is co-founder and chief strategy officer at Inato, a clinical trials platform which flips the traditional model and allows community sites to participate in the trials that are best aligned with their interests and that of their patients.

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQ’s lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical...

Public Announcement Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of...

Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO’) to manage the IND opening Phase 2/3 clinical trial investigating...

- Brings more than 20 years of academic and industry experience with extensive expertise in kidney disease - WINSTON-SALEM, N.C., July 17, 2023 (GLOBE...